On the heels of an FDA approval for its implantable continuous glucose monitoring tech, Senseonics‘ (NYSE:SENS) today priced a $130 million underwritten public offering of common stock.
The offering, which is slated to close on June 28, also includes a 30-day option for underwriters to buy additional shares of common stock worth up to $19.5 million.
Get the full story at our sister site, Drug Delivery Business News.
The post Senseonics prices $130m public offering appeared first on MassDevice.